Clinical Trials Directory

Trials / Conditions / Symptomatic COVID-19 Infection Laboratory-Confirmed

Symptomatic COVID-19 Infection Laboratory-Confirmed

14 registered clinical trials studyying Symptomatic COVID-19 Infection Laboratory-Confirmed — 2 currently recruiting.

StatusTrialSponsorPhase
CompletedClinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects
NCT06063330
Red Queen Therapeutics, Inc.Phase 1
RecruitingStudy Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock O
NCT05101213
M.D. Anderson Cancer CenterPhase 1
WithdrawnDasatinib for the Treatment of Moderate and Severe COVID-19
NCT04830735
University of Southern CaliforniaPhase 2
WithdrawnLopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the
NCT04455958
OHSU Knight Cancer InstitutePhase 2
CompletedLeflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
NCT04532372
City of Hope Medical CenterPhase 1 / Phase 2
CompletedViral Specific T Cell Therapy for COVID-19 Related Pneumonia
NCT04742595
M.D. Anderson Cancer CenterEARLY_Phase 1
WithdrawnIbrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 201
NCT04665115
Academic and Community Cancer Research UnitedPhase 2
TerminatedRintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
NCT04379518
Roswell Park Cancer InstitutePhase 1 / Phase 2
CompletedIbrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
NCT04439006
Jennifer WoyachPhase 1
RecruitingStudy of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
NCT04565665
M.D. Anderson Cancer CenterPhase 1 / Phase 2
Active Not RecruitingAnalysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
NCT04497779
City of Hope Medical Center—
UnknownBest Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
NCT04433949
Emory UniversityPhase 3
TerminatedTocilizumab for Patients With Cancer and COVID-19 Disease
NCT04370834
National Cancer Institute (NCI)Phase 2
TerminatedBaricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
NCT04373044
University of Southern CaliforniaPhase 2